Literature DB >> 25454863

Curing cervical cancer or preventing it: A case of opportunity cost in the long run?

Katelijne van de Vooren1, Alessandro Curto1, Livio Garattini2.   

Abstract

Entities:  

Keywords:  Bevacizumab; Cervical cancer; HPV vaccines; Opportunity cost

Mesh：

Substances：

Year:  2014        PMID： 25454863     DOI： 10.1016/j.vaccine.2014.10.014

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  3 in total

Review 1.  Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines.

Authors:  Julia M L Brotherton; Mark Jit; Patti E Gravitt; Marc Brisson; Aimée R Kreimer; Sara I Pai; Carole Fakhry; Joseph Monsonego; Silvia Franceschi
Journal:  Int J Cancer       Date:  2016-03-22       Impact factor: 7.396

2.  Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?

Authors:  Livio Garattini; Anna Padula
Journal:  J R Soc Med       Date:  2017-01-24       Impact factor: 5.344

3.  Pricing vaccines and drugs in Europe: worth differentiating?

Authors:  Livio Garattini; Anna Padula; Nicholas Freemantle
Journal:  Eur J Health Econ       Date:  2021-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.